Category: Articles

Whitespace Analysis vs. Patent Landscape Analysis: What Is the Difference and Which One Does Your R&D Team Actually Need?

When a Clean FTO Opinion Is Not Enough: The Four Situations That Require a Follow-Up Search

FTO in Switzerland After the 2027 Patent Act Reform: What Pharma and MedTech Companies Need to Clear Before Launch

Denmark’s Clean Energy Patent Landscape: What the IP Picture Looks Like for Wind, Hydrogen, and Heat Pump Innovation

Japan’s Life Sciences Patent Landscape: What the Post-Dapagliflozin Plausibility Standard Means for Pharma R&D Strategy

China’s CNIPA 2026 Guidelines Changed How Patents Are Examined. Has Your Competitive Landscape Caught Up?

Your Germany FTO May No Longer Be Enough: What the UPC’s Long-Arm Jurisdiction Means for Pharma and MedTech Product Launches

The UK Life Sciences Patent Landscape in 2026: What the Dapagliflozin Ruling, Patent Cliff and MHRA Reforms Mean for Your IP Strategy

The UK Just Changed How AI and Software Patents Are Assessed. Here’s What It Means for Your FTO

Japan’s University Patent Licensing Programme Is Open to Foreign Companies — and Most Haven’t Noticed

Load More